

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specific in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter dated May 20, 1992	
1. Department of Veterans Affairs		3. License number 33-15145-03 is amended in its entirety to read as follows:	
2. Veterans Administration Medical and Regional Office Center Fargo, North Dakota 58102		4. Expiration date October 31, 1991	
		5. Docket or Reference No 030-18950	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed	
D. Any byproduct material identified in 10 CFR 31.11	D. Prepackaged Kits	D. As needed	
E. Nickel-63	E. Foil (Hewlett Packard Model 2-6195) electron capture device	E. Not to exceed 15 millicuries per foil	

9212080203 921007
PDR ADOCK 03018950
C PDR

86

OFFICIAL RECORD COPY

MLAD

11/12/92

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

33-15145-03

Docket or Reference number

030-18950

Amendment No. 19

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.
- D. In vitro studies.
- E. For use in gas chromatograph for sample analysis.

CONDITIONS

- 10. Location of use: V. A. Medical and Regional Office Center, Fargo, North Dakota.
- 11. Radiation Safety Officer: Robert J. Shook, M.D.
- 12. Authorized Users:
 - A. John Jeffrey Keating, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11; nickel-63 in gas chromatographs.
 - B. R. Gilbertson, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11; nickel-63 in gas chromatographs.
 - C. D. Shook, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11; nickel-63 in gas chromatographs.
 - D. R. Marsden, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11; nickel-63 in gas chromatographs.
 - E. Bruce A. Asleson, M.D., for material identified in 10 CFR 35.100, 35.200, and 31.11; Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction; nickel-63 in gas chromatographs.
 - F. Mark F. Fisher, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11; nickel-63 in gas chromatographs.
 - G. William H. Shelver, Ph.D., for nickel-63 in gas chromatographs.
 - H. Shoukry Khalil, Ph.D., for nickel-63 in gas chromatographs.
 - I. Gerald J. Vosika, Ph.D., for material identified in 10 CFR 31.11; nickel-63 in gas chromatographs.
 - J. Gordon D. McLaren, M.D., for material identified in 10 CFR 31.11.
 - K. Robert J. Shook, M.D., for material identified in 10 CFR 35.100, 35.200, 35.300, and 31.11; nickel-63 in gas chromatographs.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

33-15145-03

Docket or Reference number

030-18950

Amendment No. 19

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee shall maintain records of information important to safe and effective decommissioning at Veterans Administration Medical and Regional Office Center, Fargo, North, Dakota, per the provision of 10 CFR 30.35(g) until this license is terminated by the Commission.
15. This license is based on the licensee's statements and representations dated as follows:
 - A. Application dated September 11, 1986
 - B. Letter dated November 14, 1988
 - C. Letter dated March 16, 1990
 - D. Letter dated May 20, 1992
 - E. Facsimile received October 5, 1992

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Original Signed By
Jacqueline D. Burks

Date OCT 7 1992

By
Nuclear Materials Licensing Section
Region IV
Arlington, Texas 76011



UNITED STATES
NUCLEAR REGULATORY COMMISSION

REGION IV

511 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TEXAS 76011-8064

OCT 7 1992

Department of Veterans Affairs
ATTN: Robert J. Shook
Radiation Safety Officer
Veterans Administration Medical
and Regional Office Center
Fargo, North Dakota 58102

Gentlemen:

Please find enclosed Amendment No. 19 to your NRC material license. You should review this amendment carefully and be sure that you understand all conditions. If you have any questions, you may contact the reviewer who signed your license amendment at 817/860-8100.

Please be advised that you must conduct your program involving radioactive materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Possess radioactive material only in the quantity and form indicated in your license.
3. Use radioactive material only for the purpose(s) indicated in your license.
4. Notify NRC in writing of any change in mailing address (no fee required if the location of radioactive material remains the same).
5. Request and obtain written NRC consent before transferring your license or any right thereunder, either voluntarily or involuntarily, directly or indirectly, through transfer of control of your license to any person or entity. A transfer of control of your license includes not only a total change of ownership, but also a change in the controlling interest in your company whether it is a corporation, partnership, or other entity. In addition, appropriate license amendments must be requested and obtained for any other planned changes in your facility or program that are contrary to your license or contrary to representations made in your license application, as well as supplemental correspondence thereto, which are incorporated into your license. A license fee may be charged for the amendments if you are not in a fee-exempt category.

6. Submit a complete renewal application with proper fee, or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.
7. Request termination of your license if you plan to permanently discontinue activities involving radioactive material.

You will be periodically inspected by NRC. A fee may be charged for inspections in accordance with 10 CFR Part 170. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Action, 10 CFR Part 2, Appendix C. Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which the NRC expects of its licensees.

Thank you for your cooperation.

Sincerely,

Original Signed By
Jacqueline D. Burks

Jacqueline D. Burks, Health Physicist
Nuclear Materials Licensing Section

Enclosure:
As stated

RIV:NMLS
JDBurks
10 16 192



DEPARTMENT OF VETERANS AFFAIRS
Medical and Regional Office Center
Fargo ND 58102

Canon Telefax Number:

FTS 783-3729 COMM: 701-239-3729

Confirmation Number:

FTS 783-3411 COMM: 701-232-3241 EX: 3411

TO: JACKIE BURKES
NRC - AMENDMENTS

FROM: JULIE VICK
NUCLEAR MEDICINE

SPECIAL INSTRUCTIONS: PRECEPTOR STATEMENTS FOR
DR. ROBERT SHOOK

FAX TO: (PHONE NUMBER) 817-860-8188

NUMBER OF PAGES:

COVER +

9

TOTAL

10

464365

ATT 7.1.1

FORM NRC-313M-SUPPLEMENT B (8-78)		U. S. NUCLEAR REGULATORY COMMISSION	
PRECEPTOR STATEMENT			
Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.			
1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C	
FULL NAME ROBERT J. SHOOK M.D.		PERSONAL PARTICIPATION SHOULD CONSIST OF:	
STREET ADDRESS 1713 8th ST. S.		1-Supervised examination of patients to determine the suitability for radiolotope diagnosis and/or treatment and recommendation for prescribed dosage.	
CITY FARGO	STATE N.DAK.	ZIP CODE 58103	2-Calibration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
		3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.	
2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN			
ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	250	SEE ATTACHED FORMS FOR LISTING OF ALL PROCEDURES PERFORMED BY ABOVE NAMED PHYSICIAN DURING TRAINING.
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	6	
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	11	
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY	2	
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING	87	
	CARDIAC IMAGING	607	
	THYROID IMAGING	76	
	SALIVARY GLAND IMAGING	4	
	BLOOD POOL IMAGING	6	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	277	
	LUNG IMAGING	90	
	BONE IMAGING	476	
OTHER			

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)
A	B	C	D
P-32 (Struble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	2/3	
P-32 (Columbia)	INTRACAVITARY TREATMENT	8	
I-131	TREATMENT OF THYROID CARCINOMA	9	
	TREATMENT OF HYPERTHYROIDISM	2	
Au-198	INTRACAVITARY TREATMENT	4	
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or In-192 Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sr-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

NOV. 1980

NOV. 1981

DEC. 1982

APRIL 1983

700 HOURS OF TRAINING

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

A. NAME OF SUPERVISOR


B. NAME OF INSTITUTION

C. MAILING ADDRESS

D. CITY

E. MATERIALS LICENSE NUMBER(S)

6. PRECEPTOR'S SIGNATURE



7. PRECEPTOR'S NAME (Please type or print)

8. DATE

6/24/83

FORM NRC-313M-SUPPLEMENT A (B-78)		U.S. NUCLEAR REGULATORY COMMISSION		
TRAINING AND EXPERIENCE AUTHORIZED USER OR RADIATION SAFETY OFFICER				
1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER		2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE N. DAKOTA, MINNESOTA		
3. CERTIFICATION				
SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C		
RADIOLOGY BOARD ELIGIBLE		OCT 83, JUNE 84		
4. TRAINING RECEIVED IN RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING		
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D	
A. RADIATION PHYSICS AND INSTRUMENTATION	RADIOLOGY RESIDENCY UNIV. OF FLOWA HOSP. & CLINICS.	100	5	
B. RADIATION PROTECTION	JULY 1980 - JUNE 1983	30		
C. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY		2.5		
D. RADIATION BIOLOGY		2.5		
E. RADIOPHARMACEUTICAL CHEMISTRY		30	5	
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
MULTIPLE PROCEDURES USING FOLLOWING RADIOPHARMACEUTICALS: ^{99m}Tc , ^{131}I , ^{123}I , ^{111}In , ^{169}Yb , ^{133}Xe , ^{127}Xe , ^{201}Tl , ^{67}Ga , ^{51}Cr , ^{125}I , ^{57}Co				

Verified accurate
 Peter J. Kirchner MD
 Director of Nucl Med
 6/24/83

IPN 6733

686

NORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES

Page 1 of 6 pages
Amendment No. 08

RADIOACTIVE MATERIAL LICENSE

Pursuant to Section 23-20.1-01 through Section 23-20.1-11 of Chapter 23-20.1 of the North Dakota Century Code, and Article 33-10 of the North Dakota Administrative Code, and in reliance on statements and representations heretofore made by the licensee designated below, a license is hereby issued authorizing such licensee to transfer, receive, possess, and use the radioactive materials for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations and orders now or hereafter in effect of the North Dakota State Department of Health and Consolidated Laboratories and to any conditions specified below:

Licensee		3. License Number 33-07824-01 is renewed and amended in its entirety.
1. Name	St. John's Hospital	4. Expiration Date
2. Address	510 Fourth Street S Fargo, ND 58103	August 31, 1996
		5. Reference Number
6. Radioactive Materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity which licensee may possess at any one time
A. Any radioactive material listed in Groups I and II of Schedule C of Chapter 33-10-03. 35, 100 35, 200	A. Any radiopharmaceutical listed in Groups I and II of Schedule C of Chapter 33-10-03.	A. As necessary for uses authorized in Subitem 9.A.
B. Any radioactive material listed in Group III of Schedule C of Chapter 33-10-03. 35, 200	B. Any radiopharmaceutical listed in Group III of Schedule C of Chapter 33-10-03.	B. 74 gigabecquerels (2 curies).
C. Any radioactive material listed in Group IV of Schedule C of chapter 33-10-03. 35, 300	C. Any radiopharmaceutical listed in Group IV of Chapter 33-10-03.	C. As necessary for uses authorized in Subitem 9.C.

733
RAD 685ANORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES

RADIOACTIVE MATERIAL LICENSE

Page 2 of 6 pages

License No. 33-07824-01

Amendment No. 08

supplemental sheet

D. Any radioactive material listed in Group V of Schedule C of Chapter 33-10-03. 30.30

D. Any radiopharmaceutical listed in Group V of Schedule C of Chapter 33-10-03.

D. As necessary for uses authorized in Subitem 9.D.

E. Any radioactive material authorized for in vitro use by Subsection 33-10-03-05.3.c.(3). 31.11

E. Any

E. As authorized by Subsection 33-10-03-04.2.g.

F. Any radioactive material authorized for use as calibration and reference standards by Subsection 33-10-03-05.3.c.(4).

F. Any

F. As authorized by Subsection 33-10-03-05.3.c.(4).

G. Cobalt 57

G. Sealed source (New England Nuclear Model NES 206)

G. No single source to exceed 185 megabecquerels (5 millicuries)

H. Radium 226

H. Sealed source (Radium Chemical Company)

H. No single source to exceed 925 megabecquerels (25 millicuries)

I. Strontium 90

I. Sealed source

I. Two sources, not to exceed 3700 megabecquerels (100 millicuries) each

J. Cobalt 57

J. Sealed source (Amersham Model CTR.29)

J. No single source to exceed 185 megabecquerels (5 millicuries)

9. Authorized Use:

- A. Any diagnostic procedure listed in Groups I and II of Schedule C of Chapter 33-10-03.

3-33
KAD 686ANORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES

Page 3 of 6 pages

License No. 33-07824-01

Amendment No. 08

RADIOACTIVE MATERIAL LICENSE

supplemental sheet

- B. Preparation and use of radiopharmaceuticals for any diagnostic procedures listed in Group III of Schedule C of Chapter 33-10-03.
- C. Any therapeutic procedure listed in Group IV of Schedule C of Chapter 33-10-03.
- D. Any therapeutic procedure listed in Group V of Schedule C of Chapter 33-10-03.
- E. In vitro uses specified in Subsection 33-10-03-04.2.g of Chapter 33-10-03.
- F. Calibration and reference standard uses specified in Subsection 33-10-03-05.3.c.(4) of Chapter 33-10-03.
- G. Reference source for dose calibrator.
- H. Storage only until disposal completed.
- I. Storage only until disposal completed.
- J. Flood source for uniformity correction.

CONDITIONS

10. The authorized place of use is the licensee's address stated in Item 2 above.
11. The licensee shall comply with the provisions of Chapter 33-10-04, "STANDARDS FOR PROTECTION AGAINST RADIATION," and Chapter 33-10-10, "NOTICES, INSTRUCTIONS AND REPORTS TO WORKERS-INSPECTIONS."
12. Radioactive materials identified in Items 6, 7 and 8 shall be used by, or under the supervision of, specific physicians as follows:

Physician

Mark Fisher, M.D.,
Radiation Safety Officer
Robert A. Shook, M.D.
Dale R. Shook, M.D.
Bruce A. Asleson, M.D.
Richard Marsden, M.D.

Authorized For

A-G, J

A-G, J

A, B, I-131 in C & D, E-G, J

A-G, J

6733
RAD 686ANORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES

RADIOACTIVE MATERIAL LICENSE

Page 4 of 6 pages

License No. 33-07824-01

Amendment No. 08

supplemental sheet

13. Except as otherwise specifically provided by this license, radioactive material to be administered to humans shall be procured in prepackaged, precalibrated, form from a supplier who manufactures or prepackages the product under appropriate pharmaceutical controls related to assay, identity, quality, purity, sterility, and nonpyrogenicity.
14. Patients containing Iodine 131 for the treatment of thyroid carcinoma or patients containing therapeutic quantities of Gold 198 shall remain hospitalized until the residual activity is 1110 megabecquerels (30 millicuries) or less.
15. A. (1) Each sealed source containing radioactive material, other than Hydrogen 3, with a half-life greater than thirty days and in any form other than gas shall be tested for leakage and/or contamination at intervals not to exceed six months. In the absence of a certificate from a transferor indicating that a test has been made within six months prior to the transfer, the sealed source shall not be put into use until tested.
- (2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source is exempt from such leak tests when the source contains 3700 kilobecquerels (100 microcuries) or less of beta and/or gamma emitting material or 370 kilobecquerels (10 microcuries) or less of alpha emitting material.
- B. The test shall be capable of detecting the presence of 185 becquerels (0.005 microcurie) of radioactive material on the test sample. The test sample shall be taken from the sealed source or from the surfaces of the device in which one might expect contamination to accumulate. Records of leak test results shall be kept in units of becquerels or microcuries and maintained for inspection by the Department.
- C. If the test reveals the presence of 185 becquerels (0.005 microcurie) or more of removable contamination, the licensee shall immediately withdraw the sealed source from use and shall cause it to be decontaminated, repaired, and retested or to be disposed of in accordance with Department rules. A report shall be filed within five days of the test with the Director, Division of Environmental Engineering, North Dakota State Department of Health and Consolidated Laboratories, Missouri Office Building, 1200 Missouri Avenue, Room 304, P.O. Box 5520, Bismarck, North Dakota, 58502-5520, describing the equipment involved, the test results, and the corrective action taken.

6733

RAD 686A

NORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES
RADIOACTIVE MATERIAL LICENSE

Page 5 of 6 pages

License No. 33-07824-01
Amendment No. 08

supplemental sheet

6. The licensee shall elute technetium 99m pertechnetate from molybdenum 99/technetium 99m generators and/or prepare radiopharmaceuticals from reagent kits in accordance with the manufacturer's specifications contained in the package insert.
17. A. Technetium-99m separated from molybdenum-99 either by elution of a molybdenum-99/technetium-99m generator or by an extraction process shall be tested to detect and quantify molybdenum-99 activity prior to administration to patients.
- B. The licensee shall not administer to patients technetium-99m containing more than 37 kilobecquerels (one microcurie) of molybdenum-99 per 37 megabecquerels (one millicurie) of technetium-99m or more than 185 kilobecquerels (five microcuries) of molybdenum-99m per dose of technetium-99m at time of administration. After March 1, 1992, the licensee shall not administer to humans a radiopharmaceutical containing more than 5550 becquerels (0.15 microcurie) of molybdenum-99 per 37 megabecquerels (1 millicurie) of technetium-99m. The limits of molybdenum-99 contamination represent maximum values and molybdenum-99 contamination should be kept as low as reasonably achievable below these limits.
- C. The licensee shall establish written procedures for personnel performing tests to detect and quantify molybdenum-99 contamination. These procedures shall include all necessary calculations and steps to be taken if activities of molybdenum-99 in excess of the limits specified in Subitem B. above are detected.
- D. Personnel performing tests to detect and quantify molybdenum-99 contamination shall be given specific training in performing tests prior to conducting such tests.
- E. The licensee shall maintain for inspection by the Department records of the results of each test performed to detect and quantify molybdenum-99 concentration and records of training given to personnel performing these tests.
18. Technetium-99m sulfur colloid preparations which appear flocculent or aggregated shall not be used in humans.
19. Sealed sources containing radioactive material shall not be opened.
20. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

6733

RAD 686A

NORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES

RADIOACTIVE MATERIAL LICENSE

Page 6 of 6 pages

License No. 33-07824-01

Amendment No. 08

supplemental sheet

- A. Affected radioactive waste shall be held for decay a minimum of ten (10) half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.
1. The licensee shall conduct a physical inventory every three (3) months to account for all sealed sources received and possessed under the license. The records of the inventories shall be maintained for inspection by the Department, and shall include the quantities and kinds of radioactive material, location of sealed sources, and the date of the inventory.
2. Except as specifically provided otherwise by this license, the licensee shall possess and use radioactive material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated July 1991 and October 10, 1991; and Radioisotope Safety Procedures Manual dated July 17, 1991.

Date:

12/7/91

FOR THE NORTH DAKOTA STATE DEPARTMENT OF HEALTH
AND CONSOLIDATED LABORATORIES

BY:

*Dana K. Mount*Dana K. Mount, P.E., Director
Div. of Environmental Engineering

464365



DEPARTMENT OF VETERANS AFFAIRS
Medical and Regional Office Center
Fargo ND 58102

May 20, 1992

* Director of Management
and Program Analysis
U.S. Nuclear Regulatory Commission
Washington, DC 20555

THRU: Regional Director (112/111E)
Department of Veterans Affairs
810 Vermont Ave. NW
Washington, DC 20420

In Reply Refer To
437/11D


AUG 26 1992

Dear Sir:


The Radiation Safety Officer requests that Section II of NRC License
#33-15145-03 be amended to name Dr. Robert Shook as Radiation Safety Officer.

I hope that this letter is of sufficient detail to permit approval of the
requested amendment.

Sincerely yours,


DONALD H. COLSTON
Center Director

Approved/Disapproved


Program Director,
Nuclear Medicine Svc. (111E)

FEE EXEMPT


4 6 4 3 6 5

Department of Veterans Affairs

MEMORANDUM

Date: July 20, 1992
From: Medical Center Director, VAMC Big Spring, TX (519/114)
Subj: Nuclear Regulatory Commission (NRC) License Amendment
To: Office of the Program Director
Nuclear Medicine Service (141A5/111E)
2200 Commonwealth Ave., Box 7
Ann Arbor, MI 48105

Attached is our request for amendment of our NRC license appointing
a new Radiation Safety Officer (RSO).


CONRAD ALEXANDER

Attachment